Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinN (1)


SARS-CoV-2 Proteins
    displaying 1 - 10 records in total 17
    records per page

    Evaluation of Patients With Covid-19 MESHD Diagnosis for Chronic Diseases MESHD

    Authors: Murat Altuntas; Habip Yilmaz; Emre Güner

    doi:10.21203/ Date: 2020-12-24 Source: ResearchSquare

    Aim: Covid-19 MESHD is one of the most important pandemics in the world history. Chronic diseases MESHD, which are risk factors that increase the case fatality rates, have been the leading cause of death MESHD all over the world. In this study, it was aimed to detect coexisting diseases in patients hospitalized with the diagnosis of Covid-19 MESHD.           Material and Method: It was carried out with the data of 229 inpatients in an intensive care unit between 01.06.2020 - 30.06.2020. Among the inclusion criteria of the study; it is necessary to have a diagnosis confirmed by PCR test, to be hospitalized in the relevant intensive care unit on the date of the study and to have data accessible through the hospital automation system. According to literature; chronic diseases of the patients and their effects on the covid-19 MESHD process were evaluated. Statistical analyzes were performed using the Statistical Package for Social Sciences (SPSS) version 24.0 (IBM Corp .; Armonk, NY, USA).Results: It was seen that the average age of the patients were 61.4±15.9 years old. While the average symptom duration was 8.2±5.3 days; total hospitalization period was 13.1±5.9 days. The length of stay of 75 patients who were sent to intensive care unit was determined as 10.1±7.1. The most common chronic disease MESHD among patients was hypertension MESHD with 47.2%. This was followed by diabetes mellitus MESHD (32.8%) and heart disease MESHD (27.5%), respectively. In the presented study, cough MESHD (59.4%), fever MESHD (58.5%) and shortness of breath MESHD (45.9%) were found to be the most common symptoms. Leukopenia MESHD, impairments in liver and muscle enzymes, abnormal C-reactive protein HGNC, ferritin and d-dimer levels were the important laboratory findings.Conclusion: Particular attention should be paid to the elderly Covid-19 MESHD patients with chronic diseases MESHD, especially DM MESHD, HT MESHD and cancer MESHD.

    Results of Favipiravir Combined Treatment in Intensive Care Patients With Covid-19 MESHD

    Authors: Habip Yilmaz; Emre Güner; Murat Altuntas

    doi:10.21203/ Date: 2020-12-19 Source: ResearchSquare

    Aim: Covid-19 MESHD ( Coronavirus disease 2019 MESHD) is a disease that has already taken place in human history. Although there is still no effective treatment and vaccine protocol, different treatment options are being tried. In this study, it was aimed to determine the basic characteristics and changes in laboratory findings of patients who were hospitalized with the diagnosis of Covid-19 MESHD in the intensive care unit and underwent treatment protocol containing favipiravir.Material and Method: It was carried out with the data of 179 inpatients in an intensive care unit between 01.06.2020 - 30.06.2020. The inclusion criterias of the study are to have a diagnosis of COVID-19 MESHD confirmed by PCR test, to be hospitalized in the intensive care unit, receiving therapy combined with favipravir and to have access to its data through the automation system. According to literature; the sociodemographic characteristics, some basic characteristics and some laboratory findings of the patients were evaluated. Statistical analyzes were performed using the Statistical Package for Social Sciences (SPSS) version 24.0 (IBM Corp .; Armonk, NY, USA).Findings: The average age of the study group is 60.9±16.4 years and 65.9% (n:118) of them are male. According to the clinical classification, more than half (50.8%, n: 91) are included in the "high" clinical classification. The most common chronic disease MESHD is " hypertension MESHD ( HT MESHD)" (42.5%, n:76) and the most common symptom is " fever MESHD" (57.5%, n: 103). While 82.7% (n: 148) have widespread CT (Computed tomography) findings, CPR HGNC ( C-Reactive protein HGNC) positivity rate is 65.4% (n: 117). Statistical significant difference was detected between three measurements of blood urea nitrogen (BUN), aspartat aminotransferase ( AST HGNC), alanin aminotransfrase (ALT), CRP HGNC between the 1st and the 3rd day. Conclusion: Favipiravir demonstrates a proper safety profile. However, its side effects teratogenicity, hyperuricaemia and QTc MESHD (corrected QT interval) prolongation have not yet been adequately studied. It may be safe and tolerable in short-term use, but more evidence is needed to assess the longer-term effects of treatment.

    Epidemiological, clinical, and laboratory findings for patients of different age groups with confirmed coronavirus disease 2019 MESHD ( COVID-19 MESHD) in a hospital in Saudi Arabia

    Authors: Mutasim E Ibrahim; Obaid S AL-Aklobi; Mosleh M Abomughaid; Mushabab A. Al-Ghamdi

    doi:10.1101/2020.10.21.20217083 Date: 2020-10-25 Source: medRxiv

    Background: Although the coronavirus disease 2019 MESHD ( COVID-19 MESHD) pandemic continues to rage worldwide, clinical and laboratory studies of this disease have been limited in many countries. We investigated the epidemiologic, clinical, and laboratory findings of COVID-19 MESHD infected MESHD patients to identify the effective indicators correlated with the disease. Methods: A retrospective study was conducted at King Abdullah Hospital in Bisha Province, Saudi Arabia, from March 20 to June 30, 2020. Patients of different age groups were confirmed as having COVID-19 MESHD infection using a real-time polymerase chain reaction. The demographic, clinical, and laboratory data of the patients were statistically analyzed. Results: Of the 137 patients, 88 were male and 49 were female, with a mean age of 49.3 years (SD,18.4). The patients were elderly (n=29), adults (n=103), and children (n=5). Of these, 54 (39.4%) had comorbidities, 24% were admitted to the intensive care unit (ICU), and 12 (8.8%) died. On admission, the main clinical manifestations were fever MESHD (82.5%), cough (63.5%), shortness of breath MESHD (24.8%), chest pain MESHD (19.7%), and fatigue MESHD (18.2%). In all patients, increased neutrophils and decreased lymphocytes were observed. Patients' lactate dehydrogenase (LDH) was elevated. C-reactive protein HGNC ( CRP HGNC) was elevated in 46.7%, D-dimer in 41.6%, and the erythrocyte sedimentation rate (ESR) in 39.4% of patients. The elderly showed higher neutrophil (p=0.003) and lower lymphocyte (p=0.001) counts than adults and children. Glucose, creatine kinase-MB, LDH, bilirubin, D-dimer, and ESR were significantly higher in the elderly than in the adults. The COVID-19 MESHD death group had a higher leucocyte count (p = 0.043), and higher urea (p=0.025) and potassium (p=0.026) than the recovered group but had a lower hemoglobin concentration (p=0.018). A significant association was determined between COVID-19 MESHD death MESHD (x2(1)=17.751, p<0.001), and the presence of cardiovascular disease MESHD (x2(1)=17.049, p<0.001), hypertension MESHD (x2(1)=7.659, p=0.006), renal failure MESHD (x2(1)=4.172, p<0.04), old age (t(135) = 4.747, p <0.001), and ICU admission (x2(1) = 17.751 (1), p<0.001). Conclusions: The common symptoms found in this study could be useful for identifying potential COVID-19 MESHD patients. Investigating some of the laboratory and clinical parameters could help assess the disease progression, risk of mortality, and follow up patients who could progress to a fatal condition.

    Patient characteristics and predictors of mortality in 470 adults admitted to a district general hospital in England with Covid-19 MESHD

    Authors: Joseph V Thompson; Nevan Meghani; Bethan M Powell; Ian Newell; Roanna Craven; Gemma Skilton; Lydia J Bagg; Irha Yaqoob; Michael J Dixon; Eleanor J Evans; Belina Kambele; Asif Rehman; Georges Ng Man Kwong

    doi:10.1101/2020.07.21.20153650 Date: 2020-07-27 Source: medRxiv

    Background Understanding risk factors for death MESHD in Covid 19 is key to providing good quality clinical care. Due to a paucity of robust evidence, we sought to assess the presenting characteristics of patients with Covid 19 and investigate factors associated with death MESHD. Methods Retrospective analysis of adults admitted with Covid 19 to Royal Oldham Hospital, UK. Logistic regression modelling was utilised to explore factors predicting death. Results 470 patients were admitted, of whom 169 (36%) died. The median age was 71 years (IQR 57 to 82), and 255 (54.3%) were men. The most common comorbidities were hypertension MESHD (n=218, 46.4%), diabetes MESHD (n=143, 30.4%) and chronic neurological disease MESHD (n=123, 26.1%). The most frequent complications were acute kidney injury MESHD (n=157, 33.4%) and myocardial injury MESHD (n=21, 4.5%). Forty three (9.1%) patients required intubation and ventilation, and 39 (8.3%) received non-invasive ventilation Independent risk factors for death MESHD were increasing age (OR per 10 year increase above 40 years 1.87, 95% CI 1.57 to 2.27), hypertension MESHD (OR 1.72, 1.10 to 2.70), cancer MESHD (OR 2.20, 1.27 to 3.81), platelets <150x103/microlitre (OR 1.93, 1.13 to 3.30), C-reactive protein HGNC >100 micrograms/mL (OR 1.68, 1.05 to 2.68), >50% chest radiograph infiltrates, (OR 2.09, 1.16 to 3.77) and acute kidney injury MESHD (OR 2.60, 1.64 to 4.13). There was no independent association between death MESHD and gender, ethnicity, deprivation level, fever MESHD, SpO2/FiO2 (oxygen saturation index), lymphopenia MESHD or other comorbidities. Conclusions We characterised the first wave of patients with Covid 19 in one of Englands highest incidence areas, determining which factors predict death. These findings will inform clinical and shared decision making, including the use of respiratory support and therapeutic agents.

    Clinical Characteristics of SARS-CoV-2 pneumonia diagnosed in a primary care practice in Madrid (Spain)

    Authors: Marina Guisado-Clavero; Ana Herrero Gil; Marta Pérez Álvarez; Marta Castelo Jurado; Ana Herrera Marinas; Vanesa Aguilar Ruiz; Ileana Gefaell Iarrondo; Miguel Menéndez; Sara Ares-Blanco

    doi:10.21203/ Date: 2020-07-13 Source: ResearchSquare

    Background: Possible cases of SARS-CoV-2 infection MESHD were diagnosed in primary care in Madrid, some of these cases had pneumonia MESHD. Most of the SARS-CoV-2 pneumonia MESHD published data came from hospitalised patients. This study set out to describe clinical characteristics of patients with SARS-CoV-2 pneumonia MESHD diagnosed in primary care across age groups and type of pneumonia MESHD.Methods: Observational retrospective study obtaining clinical data from the electronic health records of patients who were followed-up by SARS-CoV-2 possible infection in a primary care practice in Madrid. All the cases were collected by in-person or remote consultation during the 10th March to the 7th of April. Exposure: Diagnosis of SARS-CoV-2 pneumonia MESHD by chest X-ray ordered by the GP. Main outcomes and measures: Symptoms of SARS-CoV-2 pneumonia MESHD, physical examination and diagnostic tests as a blood test, nasopharyngeal swab results for RT-PCR (Reverse transcriptase-polymerase chain reaction) and chest X-ray results. Results: The overall SARS-CoV-2 pneumonias MESHD collected were 172 (female 87 [50.6%], mean age 60.5 years (standard deviation [SD] 17.0). Comorbidities were body mass index ≥25 kg/m 2 (90 [52.3%]), hypertension MESHD 83 [48.3%]), dyslipidaemia (68 [39.5%]) and diabetes MESHD (33 [19.2%]). The sample was stratified by age groups (<50 years, 50-75 years and ≥75 years). Clinical manifestations at onset were fever MESHD (144 [83.7%]), cough (140 [81.4%]), dyspnoea MESHD (103 [59.9%]) and gastrointestinal disturbances MESHD (72 [41.9%]). Day 7.8 (SD:4.1) from clinical onset was the mean day of pneumonia MESHD diagnosis. Bilateral pneumonia MESHD was more prevalent than unilateral (126 [73.3%]) and 46 [26.7%]). Patients with unilateral pneumonia MESHD were prone to higher pulse oximetry (96% vs 94%, p <0.001). We found differences between unilateral and bilateral cases in C-reactive protein HGNC (29.6 vs 81.5mg/L, p <0.001), and lymphocytes (1400.0 vs 1000.0E3/ml, p<0.001). Complications were registered: 42 (100%) of patients ≥75 years were admitted into hospital; pulmonary embolism MESHD was only present at bilateral pneumonia MESHD (7 patients [5.6%]) and death MESHD occurred in 1 patient with unilateral pneumonia MESHD (2.2%) vs 10 patients (7.9%) with bilateral pneumonia MESHD ( p 0.170).Conclusion: Clinical manifestations of SARS-CoV-2 pneumonia MESHD were fever MESHD, cough and dyspnoea MESHD; this was especially clear in the elderly. We described different characteristics between unilateral and bilateral pneumonia MESHD.

    What is the clinical course of patients hospitalised for COVID-19 MESHD treatment Ireland: a retrospective cohort study in Dublin’s North Inner City (the ‘Mater 100’)

    Authors: Brendan O’Kelly*; Colm Cronin*; Stephen Peter Connolly*; Walter Cullen; Gordana Avramovic; Tina McHugh; Eileen O’Connor; Aoife Cotter; Peter Doran; Tara McGinty; Dermot O’Callaghan; Sean Gaine; Gerard Sheehan; Eamonn Brazil; Brian Marsh; John S. Lambert

    doi:10.21203/ Date: 2020-06-08 Source: ResearchSquare

    Background: Since March 2020, Ireland has experienced an outbreak of coronavirus disease 2019 MESHD ( COVID-19 MESHD), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, while several cohorts from China have been described, our understanding is limited, with no data describing the epidemiological and clinical characteristics of patients with COVID-19 MESHD in Ireland. To improve our understanding of the clinical characteristics of this emerging infection we carried out a retrospective review of patient data to examine the clinical characteristics of patients admitted for COVID-19 MESHD hospital treatment.Methods: Demographic, clinical and laboratory data on the first 100 adult patients admitted to Mater Misericordiae University Hospital (MMUH) for in-patient COVID-19 MESHD treatment after onset of the outbreak in March 2020 was extracted from clinical and administrative records. Missing data were excluded from the analysis.Results: Fifty-eight per cent were male, 63% were Irish nationals, 29% were GMS eligible, and median age was 45 years (interquartile range [IQR] =34-64 years). Patients had symptoms for a median of five days before diagnosis (IQR=2.5-7 days), most commonly cough (72%), fever MESHD (65%), dyspnoea MESHD (37%), fatigue MESHD (28%), myalgia MESHD (27%) and headache MESHD (24%). Of all cases, 54 had at least one pre-existing chronic illness (most commonly hypertension MESHD, diabetes mellitus MESHD or asthma MESHD). At initial assessment, the most common abnormal findings were: C-reactive protein HGNC >7.0mg/L (74%), ferritin >247μg/L (women) or >275μg/L (men) (62%), D-dimer >0.5μg/dL (62%), chest imaging (59%), NEWS Score (modified) of ≥3 (55%) and heart rate >90/min (51%). Twenty-seven required supplemental oxygen, of which 17 were admitted to the intensive care unit - 14 requiring ventilation. Forty received antiviral treatment (most commonly hydroxychloroquine or lopinavir/ritonavir). Four died, 17 were admitted to intensive care, and 74 were discharged home, with nine days the median hospital stay (IQR=6-11).Conclusion: Our findings reinforce the emerging consensus of COVID-19 MESHD as an acute life-threatening disease and highlights, the importance of laboratory (ferritin, C-reactive protein HGNC, D-dimer) and radiological parameters, in addition to clinical parameters. Further cohort studies involving larger samples followed longitudinally are a priority.

    Comparison of the Clinical Characteristics of Patients With COVID-19 MESHD in Suining and Wuhan

    Authors: Xiao-juan Wu; Chao-Ping Wang; Xiao-Bin Luo; Gao-Yan He; Bao-Lin Jia; Jing Wang; Li Luo; Rong Qiu; Zheng-Guang He; Min-Chao Li

    doi:10.21203/ Date: 2020-05-30 Source: ResearchSquare

     Background Coronavirus disease 2019 MESHD ( COVID-19 MESHD), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first identified in December 2019 in Wuhan. This study mainly analyzed the clinical characteristics, imaging features, and prognosis of patients with COVID-19 MESHD in Suining, one of China's fourth-tier cities, and Wuhan in 2019 and compared data between the 2 cities. Methods A retrospective analysis of the epidemiological history, clinical data, symptom presentation, laboratory test results, chest computed tomography (CT) imaging features, treatment measures and prognosis of 68 patients with COVID-19 MESHD diagnosed at Wuhan Red Cross Hospital and 17 patients with COVID-19 MESHD diagnosed at Suining Central Hospital from January 23, 2020, to February 27, 2020, was conducted. Results 1) The incidence rate of COVID-19 MESHD in Wuhan was 52.99‱, and the incidence rate in Suining was 0.04‱. The median age of patients with COVID-19 MESHD was 40.71 years old in Suining and 56.04 years old in Wuhan. The age of patients with COVID-19 MESHD in Wuhan was significantly older than that of patients with COVID-19 MESHD in Suining. Among the 68 patients with COVID-19 MESHD in Wuhan, 30 (44.1%) had hypertension MESHD, and 25 (36.8%) had diabetes MESHD. Three out of the 17 patients in Suining (17.6%) had hypertension MESHD, and 2 patients (11.8%) had diabetes MESHD. The proportion of patients with diabetes MESHD or hypertension MESHD in Wuhan was significantly higher than that in Suining (P<0.05). In the clinical classification, there were 1 (5.9%) and 23 (33.8%) patients with severe COVID-19 MESHD in Suining and Wuhan, respectively. The proportion of patients with severe COVID-19 MESHD in Wuhan was significantly higher than that in Suining (P<0.05). Fever MESHD and cough MESHD were the most common clinical symptoms, with 9 cases (52.9%) and 8 cases (47.1%) in Suining, respectively, and 54 cases (79.4%) and 42 cases (61.8%) in Wuhan, respectively. There was 1 patient (5.9%) with COVID-19 MESHD with dyspnea MESHD in Suining and 23 patients (33.8%) with COVID-19 MESHD with dyspnea MESHD in Wuhan; the difference was statistically significant (P<0.05). Chest CT showed that lung consolidation occurred in 2 (11.8%) and 26 (38.2%) patients with COVID-19 MESHD in Suining and Wuhan, respectively. The proportion of lung consolidation in patients in Wuhan was significantly higher than that in patients in Suining (P<0.05). The laboratory tests suggested that percentage ofelevated C-reactive protein HGNC ( CRP HGNC) (58.8%), ALT (33.8%), blood glucose (45.6%), creatine kinase (CK) (33.8%) or D-dimer (47.1%) of patients in Wuhan were significantly increased than those in Suining (29.4%, 5.9%, 17.6%, 5.9%, and 17.7%, respectively). Moreover, the average length of hospital stay of patients in Wuhan was 17.49 days, which was significantly longer than that of patients in Suining (12.29 days). Conclusions The incidence of COVID-19 MESHD in fourth-tier cities, Suining, in China was significantly lower than that in Wuhan, and the disease severity was generally lower than that in Wuhan, with mostly good prognoses. Advanced age, diabetes MESHD, and hypertension MESHD are important factors that aggravate COVID-19 MESHD, while elevated CRP HGNC, ALT, blood glucose, CK, and D-dimer levels are important indicators for severe disease. 

    Clinical Features of Hypertensive Patients With Covid-19 MESHD Compared With a Normotensive Group

    Authors: shuang wang; qiang zhang; zhao bin zheng; peng wang; hua hong ye; xiao qing jing; jun hua zhang; da yu fan; ping jia; zhong dan zhang; ting ting luo; shi sheng zhu

    doi:10.21203/ Date: 2020-05-26 Source: ResearchSquare

    Background: The novel coronavirus ( COVID-19 MESHD), which began in Wuhan, China, in December 2019, has spread worldwide and poses a great threat to human health. Among COVID-19 MESHD patients, those with hypertension MESHD have been reported to have higher morbidity and mortality. This study was conducted to provide the international community with a deeper understanding of COVID-19 MESHD with hypertension MESHD.Methods: A total of 188 COVID-19 MESHD patients were studied from January to March 2020. The epidemiology, clinical features, and laboratory data of hypertensive MESHD patients with COVID-19 MESHD were collected, retrospectively analyzed, and compared with a normotensive group. The use of anti- hypertensive MESHD drugs, general treatment, and clinical outcomes of hypertensive MESHD patients were also analyzed.Results: The median ages in hypertensive MESHD patients with mild and severe COVID-19 MESHD were both significantly greater than the median age in the normotensive group. But there was no significant gender difference between the hypertensive MESHD and normotensive groups. All patients had lived in the Wuhan area. Common symptoms of all of the patients included fever MESHD, cough MESHD, and fatigue MESHD. Chest CT scans showed bilateral patchy shadows or ground glass opacity in the lungs of all of the patients. All (98 [100%]) of the hypertensive MESHD patients received antiviral therapy (Arbidol was used alone or in combination with Ribavirin), antibiotic therapy (85 [86.7%]), and corticosteroids (31 [31.6%]). It has been suggested that the combination of Arbidol and Ribavirin as initial therapy for hypertensive MESHD patients with COVID-19 MESHD is effective and safe. There were no significant differences in laboratory data between the mild cases in the hypertensive MESHD and the normotensive groups. In the severe cases, the hypertensive MESHD patients had higher plasma levels of D-dimer, C-reactive protein HGNC ( CRP HGNC), and Interleukin-6 HGNC ( IL-6 HGNC) (P < 0.05). Furthermore, the hypertensive MESHD patients who were treated with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) had no statistically significant differences between the mild and severe groups (p > 0.05).Conclusion: In this study, we demonstrated that the hypertensive MESHD patients who were treated with ACEI/ARB did not have an increased risk of developing severe COVID-19 MESHD. Arbidol and Ribavirin played an important role in the treatment of the viral pneumonia MESHD. Hypertensive MESHD patients with severe viral pneumonia MESHD had stronger inflammatory responses than non- hypertensive MESHD patients.

    Early effect of SARS-COV-2 on renal tubule: a pilot study

    Authors: Mengyan Wang; Xiaotian Dong; Jun Yan; Zhongdong Zhang; Jinchuan Shi; Shourong Liu

    doi:10.21203/ Date: 2020-05-12 Source: ResearchSquare

    Objective: To explore the early clinical characteristics of coronavirus disease 2019 MESHD ( COVID-19 MESHD) and provide a reference for the early prevention and treatment of the disease.Methods: We collected and analyzed demographic data, medical history, exposure history, underline diseases MESHD, symptoms, signs, laboratory data, chest computed tomographic (CT) scans, and treatment measures of COVID-19 MESHD patients admitted to the Sixth People's Hospital of Hangzhou from January 20 to February 23, 2020.Results: Among 51 confirmed COVID-19 MESHD patients included in this study, 7.8% (4/51) patients were severe and 45.1% (23/51) were male. Median age was 43 years (IQR, 23). Fever MESHD (54.9%, 28/51) and cough (52.9%, 27/51) were the main symptoms. 74.5% (38/51) patients had a history of exposure and 17.6% (9/51) patients had a history of hypertension MESHD. Importantly, most (60.8%, 31/51) patients had an increase of urine β2 microglobulin HGNC. In addition, the inflammation MESHD indexes ( C-reactive protein HGNC and serum amyloid A) of patients with elevated urine β2 microglobulin HGNC were significantly increased (p = 0.017 and p = 0.049) and lymphocytes count was significantly reduced (p = 0.012), compared with patients with normal urine β2 microglobulin HGNC. Correlation analysis showed that urine β2 microglobulin HGNC was positively correlated with C-reactive protein HGNC and serum amyloid A; but negatively correlated with lymphocytes count.Conclusions: COVID-19 MESHD patients have obvious symptoms of lung injury MESHD, but the occurrence of early renal tubular injuries MESHD has to be monitored vigilantly.

    Clinical Characteristics and Risk factors for developed COVID-19 MESHD patients transferring to designated hospital from Jianghan Fangcang shelter Hospital: a retrospective, observational study

    Authors: Yunfei Liao; Yong Feng; Bo Wang; Hanyu Wang; Jinsha Huang; Yaxin Wu; Ziling Wu; Xiao Chen; Chao Yang; Xinqiao Fu; Hui Sun

    doi:10.1101/2020.04.21.20074724 Date: 2020-04-24 Source: medRxiv

    Background The outbreak of coronavirus disease 2019 MESHD ( COVID-19 MESHD) has become a world-wide emergency. Fangcang shelter hospitals have been applied in COVID-19 MESHD to ease ongoing shortage of medical resources in Wuhan since February 2020. Methods This study enrolled all cases (no=1848) with mild or moderate type of COVID-19 MESHD in Fangcang shelter hospital of Jianghan in Wuhan from Feb 5th to Mar 9th, 2020. Diagnosis of COVID-19 MESHD was based on the National health commission of China. Epidemiological history, comorbidity, vital signs, symptoms and signs were recorded in detail. Laboratory tests included biochemical indicators and nucleic acid tests by throat swabs have been performed as well. Findings A total of 1327 patients reached the criteria of isolation release. Meanwhile, 521 patients have been transferred to the designated hospitals for further treatment, including severe type, fever MESHD more than 3 days, and severe comorbidity. The case-severity rate (rate of mild or moderate type transforming to severe type) was 3.0% in the shelter hospital. The patients from mild or moderate type to severe type showed the following clinical characteristics: the median incubation (onset to shelter) period was 10 days; they were all symptomatic at admission; fever MESHD, cough MESHD, and fatigue MESHD were the most common symptoms; hypertension MESHD, diabetes MESHD and coronary heart diseases MESHD were common co-morbidities; most of the patients had elevated levels of CRP HGNC at ill onset with 33.3% over 10 mg per L; bilateral distribution and ground-glass opacity were the most common manifestations in chest CT. Interpretation The potential risk factors of fever MESHD, fatigue MESHD, high level of C-reactive protein HGNC were the risk factors to identify the progression of COVID-19 MESHD patients with mild or moderate type. Fangcang shelter hospitals have substantially reduced the time from the onset of severe symptoms transfer to a designated hospital. Early application of the Fangcang shelter hospital may contribute to decrease the ratio of mild transforming to severe patients. Funding No specific grant from any funding was applied to this research.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.